Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(23 days ago) | |
US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(23 days ago) |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 27 March, 1998
Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: TABLET;ORAL
7
Korea, Republic of
6
European Union
5
United States
5
Japan
3
Australia
2
Spain
2
Malaysia
2
Denmark
2
Poland
2
China
2
Russia
2
Canada
2
Argentina
2
Norway
2
New Zealand
2
Cyprus
2
Israel
2
Portugal
2
Slovenia
1
Uruguay
1
Panama
1
Austria
1
Hong Kong
1
Germany
1
Brazil
1
Croatia
1
Guatemala
1
Peru
1
Taiwan
1
Mexico
1
Ecuador
1
South Africa
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(20 days ago) |
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
13
United States
4
China
4
European Union
3
Japan
3
Korea, Republic of
2
Argentina
1
Spain
1
Austria
1
Malaysia
1
Denmark
1
Germany
1
Poland
1
Yugoslavia
1
Brazil
1
Canada
1
Ukraine
1
EA
1
Norway
1
ME
1
New Zealand
1
Croatia
1
Israel
1
Portugal
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(28 days ago) |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1998
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: INJECTABLE;INJECTION; SOLUTION;INJECTION
8
United States
1
Canada
1
Japan
1
Australia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7540282 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(23 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
16
United States
6
Spain
6
Australia
6
European Union
5
Uruguay
5
Korea, Republic of
5
United Kingdom
5
Peru
5
Canada
5
Portugal
5
Taiwan
5
Japan
5
Denmark
4
Austria
3
Germany
3
Cyprus
3
Argentina
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8183295 | NOVARTIS | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
May, 2023
(13 days ago) |
Market Authorisation Date: 21 December, 2010
Treatment: NA
Dosage: TABLET;ORAL
4
United States
3
Korea, Republic of
3
European Union
2
Japan
1
Spain
1
Austria
1
Hong Kong
1
Denmark
1
Poland
1
China
1
Russia
1
Brazil
1
Canada
1
Norway
1
New Zealand
1
Cyprus
1
Israel
1
Portugal
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Luxembourg
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7540282 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(23 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
16
United States
6
Spain
6
Australia
6
European Union
5
Uruguay
5
Korea, Republic of
5
United Kingdom
5
Peru
5
Canada
5
Portugal
5
Taiwan
5
Japan
5
Denmark
4
Austria
3
Germany
3
Cyprus
3
Argentina
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(15 days ago) |
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 14 November, 2008
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(23 days ago) | |
US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(23 days ago) | |
US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(23 days ago) |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention ...
Dosage: TABLET;ORAL
7
Korea, Republic of
6
European Union
5
United States
5
Japan
3
Australia
2
Spain
2
Malaysia
2
Denmark
2
Poland
2
China
2
Russia
2
Canada
2
Argentina
2
Norway
2
New Zealand
2
Cyprus
2
Israel
2
Portugal
2
Slovenia
1
Uruguay
1
Panama
1
Austria
1
Hong Kong
1
Germany
1
Brazil
1
Croatia
1
Guatemala
1
Peru
1
Taiwan
1
Mexico
1
Ecuador
1
South Africa
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7595021 | SAGE PRODS | Method of providing alcohol-free disinfection |
May, 2023
(17 days ago) |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: CLOTH;TOPICAL
7
United States
2
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(13 days ago) | |
US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(13 days ago) |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: NA
Dosage: TABLET;ORAL
8
United States
4
China
3
Japan
3
Korea, Republic of
3
Peru
3
European Union
2
Hong Kong
2
Russia
2
Brazil
2
Canada
2
Argentina
2
Norway
2
New Zealand
2
Taiwan
2
Mexico
2
Australia
2
Ecuador
2
South Africa
1
Spain
1
Austria
1
Malaysia
1
Denmark
1
Poland
1
Germany
1
Morocco
1
Cyprus
1
Chile
1
Israel
1
Portugal
1
Egypt
1
Tunisia
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6913768 | TAKEDA PHARMS USA | Sustained release delivery of amphetamine salts |
May, 2023
(5 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Mar 13, 2023 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
4
United States
1
Spain
1
Austria
1
Hong Kong
1
Iceland
1
Denmark
1
AP
1
Germany
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
Norway
1
Japan
1
OA
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
South Africa
1
Slovenia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8118802 | FRESENIUS KABI USA | Connector for packaging containing medical fluids and packaging for medical fluids |
May, 2023
(11 days ago) |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 September, 1996
Treatment: NA
Dosage: SOLUTION;INJECTION
4
European Union
2
United States
2
Germany
1
Spain
1
Hong Kong
1
Austria
1
India
1
Denmark
1
Poland
1
China
1
Brazil
1
Canada
1
Norway
1
Japan
1
Korea, Republic of
1
Portugal
1
Mexico
1
Australia
1
South Africa
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9220747 | FERRING PHARMS INC | Methods using desmopressin acetate in orodispersible form |
May, 2023
(22 days ago) | |
US9504647 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(22 days ago) | |
US9919025 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(22 days ago) | |
US10307459 | FERRING PHARMS INC | Pharmaceutical formulations of desmopressin |
May, 2023
(22 days ago) |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults
Dosage: TABLET;SUBLINGUAL
15
United States
3
Argentina
3
Australia
2
Uruguay
2
IB
2
Germany
2
China
1
Spain
1
Austria
1
Hong Kong
1
Malaysia
1
Denmark
1
Poland
1
United Kingdom
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Norway
1
Japan
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
South Africa
1
Slovenia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7579321 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(23 days ago) | |
US7405203 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(23 days ago) |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: A method of treating nocturia due to nocturnal polyuria in adults
Dosage: SPRAY, METERED;NASAL
15
United States
3
Argentina
3
Australia
2
Uruguay
2
IB
2
Germany
2
China
1
Spain
1
Austria
1
Hong Kong
1
Malaysia
1
Denmark
1
Poland
1
United Kingdom
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Norway
1
Japan
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
South Africa
1
Slovenia
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8673939 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(14 days ago) | |
US8735428 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(14 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Nov 20, 2023 |
Orphan Drug Exclusivity (ODE) | May 14, 2027 |
Pediatric Exclusivity (PED) | May 20, 2024 |
Drugs and Companies using POMALIDOMIDE ingredient
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a pro...
Dosage: CAPSULE;ORAL
89
United States
27
Canada
26
China
24
European Union
23
Japan
13
New Zealand
13
Korea, Republic of
13
Australia
11
Mexico
9
Hong Kong
8
Israel
7
Spain
7
Denmark
7
Portugal
7
South Africa
6
Norway
6
Taiwan
5
Poland
5
Brazil
4
Cyprus
4
Costa Rica
4
Slovenia
3
Russia
3
Ukraine
3
Argentina
3
ME
3
Hungary
2
Austria
2
Iceland
2
RS
2
Peru
2
Ecuador
1
AP
1
Germany
1
Yugoslavia
1
Morocco
1
EA
1
OA
1
Croatia
1
Georgia
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7540282 | TEVA BRANDED PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(23 days ago) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
16
United States
6
Spain
6
Australia
6
European Union
5
Uruguay
5
Korea, Republic of
5
United Kingdom
5
Peru
5
Canada
5
Portugal
5
Taiwan
5
Japan
5
Denmark
4
Austria
3
Germany
3
Cyprus
3
Argentina
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(8 days ago) | |
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(9 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 20 November, 2008
Treatment: Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic imm...
Dosage: TABLET;ORAL
8
United States
2
Japan
2
Korea, Republic of
2
European Union
1
Spain
1
Hong Kong
1
Austria
1
Malaysia
1
Iceland
1
Denmark
1
Poland
1
Germany
1
Russia
1
China
1
Brazil
1
Canada
1
Argentina
1
Norway
1
New Zealand
1
Cyprus
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Australia
1
South Africa
1
Lithuania
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(8 days ago) | |
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(9 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
ODE* (ODE*) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in patients with chronic hepatitis...
Dosage: FOR SUSPENSION;ORAL
8
United States
2
Japan
2
Korea, Republic of
2
European Union
1
Spain
1
Hong Kong
1
Austria
1
Malaysia
1
Iceland
1
Denmark
1
Poland
1
Germany
1
Russia
1
China
1
Brazil
1
Canada
1
Argentina
1
Norway
1
New Zealand
1
Cyprus
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Australia
1
South Africa
1
Lithuania
1
Slovenia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648095 | CELGENE | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(14 days ago) | |
US9101621 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(14 days ago) | |
US8530498 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(14 days ago) | |
US9101622 | CELGENE | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(14 days ago) | |
US9155730 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(14 days ago) | |
US9393238 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(14 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 27 December, 2005
Treatment: Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of patients with multiple myelom...
Dosage: CAPSULE;ORAL
89
United States
27
Canada
26
China
24
European Union
23
Japan
13
New Zealand
13
Korea, Republic of
13
Australia
11
Mexico
9
Hong Kong
8
Israel
7
Spain
7
Denmark
7
Portugal
7
South Africa
6
Norway
6
Taiwan
5
Poland
5
Brazil
4
Cyprus
4
Costa Rica
4
Slovenia
3
Russia
3
Ukraine
3
Argentina
3
ME
3
Hungary
2
Austria
2
Iceland
2
RS
2
Peru
2
Ecuador
1
AP
1
Germany
1
Yugoslavia
1
Morocco
1
EA
1
OA
1
Croatia
1
Georgia
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(4 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Oct 30, 2023 |
Pediatric Exclusivity (PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
Market Authorisation Date: 04 November, 2016
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7501409 | METUCHEN PHARMS | Preparations for oral administration |
May, 2023
(24 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
Market Authorisation Date: 27 April, 2012
Treatment: NA
Dosage: TABLET;ORAL
4
Japan
2
Australia
1
New Zealand
1
United States
1
Korea, Republic of
1
China
1
Spain
1
Hong Kong
1
Austria
1
Canada
1
Mexico
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic